Form 4: Abbott CEO Ford Sells Shares for Tax Obligation

Abbott Laboratories' Chairman and CEO, Robert B. Ford, disposed of 30,308 common shares to cover tax liabilities at a price of $116.26 per share.

Summary

• Robert B. Ford, Chairman and CEO of Abbott Laboratories (ABT), reported a transaction involving the disposal of common shares.
• On February 27, 2026, Ford disposed of 30,308 common shares without par value.
• The shares were disposed of at a price of $116.26 per share, typically for tax withholding purposes.
• Following this transaction, Ford directly beneficially owns 306,461 common shares.
• Additionally, Ford indirectly beneficially owns 216,203 common shares held in the Ford Family Trust, for which he is a co-trustee.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The disposal of shares is for tax purposes and was executed under a 10b5-1 plan, which is a routine occurrence for executives and generally not indicative of a change in company fundamentals or management's outlook.

Negatives

• A disposal of 30,308 common shares by the Chairman and CEO, even for tax purposes, represents a reduction in direct insider ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales for tax obligations, especially when executed under a pre-arranged Rule 10b5-1 plan, are a common occurrence and typically do not signal a change in management's long-term confidence or the company's strategic direction. Such transactions are often part of routine compensation and tax planning for executives.

Corporate Governance

Related Party Transactions

• Robert B. Ford indirectly beneficially owns 216,203 common shares held in the Ford Family Trust, of which he is a co-trustee. This represents a related party holding.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the overall impact on shareholder confidence is likely minimal given the routine nature of tax-related sales under a 10b5-1 plan.

Key Dates

Recommendation

This Form 4 reports a routine disposal of shares by the CEO to cover tax liabilities, executed under a Rule 10b5-1 plan. Such transactions are common and generally do not signal a change in the company's fundamentals or management's long-term confidence, thus a 'hold' recommendation is appropriate as it doesn't provide new information to alter an existing investment thesis.

Keywords

Abbott Laboratories, ABT, Form 4, Insider Transaction, Robert B. Ford, CEO, Share Sale, Tax Withholding, 10b5-1 Plan